<DOC>
	<DOCNO>NCT02239835</DOCNO>
	<brief_summary>Objectives study evaluate efficacy safety two different dos tipranavir ( TPV ) combination ritonavir ( TPV/r ) compare standard dual PI combination saquinavir ( SQV ) ritonavir ( RTV ) evaluate dose response two different dos TPV combination RTV efficacy safety .</brief_summary>
	<brief_title>Tipranavir Ritonavir vs. Saquinavir Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors Single Protease Inhibitor-experienced HIV-1 Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Clinical failure current PIcontaining regimen indinavir , nelfinavir , amprenavir In investigator 's opinion , adherence present PIcontaining regimen Exposure &gt; =6 month current PI therapy Stable PIcontaining regimen , i.e. , receive current two reverse transcriptase inhibitor ( RTIs ) least 2 month prior study entry HIV1 RNA &gt; =1000 copies/mL ( assay use Amplicor polymerase chain reaction ( PCR ) method initial screen visit ) No limit CD4+ cell count initial screening At least two new nucleoside reverse transcriptase inhibitor ( NRTI ) option available Age &gt; =18 year Acceptable screen laboratory test value indicate adequate baseline organ function time screen . Acceptable laboratory test value consist follow : severity &lt; =Grade 1 ( ACTG Grading Scale ) . Stable Grade 2 abnormality permit value demonstrate document least &gt; =2 month . All laboratory value &gt; Grade 2 subject approval P &amp; U Clinical Program Leader designate personnel subsequently BI designate personnel Acceptable medical history , physical examination , ECG , chest radiograph prior entry treatment phase study Use barrier contraceptive method birth control least 30 day prior study drug administration , study , 30 day study completion Ability swallow numerous tablet capsule without difficulty Ability understand provide inform consent . Minors approval parent legal guardian Treatment one PIcontaining regimen Clinically significant active acute ( onset within month previous study entry ) medical problem , include follow : opportunistic infection , e.g. , active cryptococcosis , Pneumocystis carinii pneumonia , herpes zoster , histoplasmosis , cytomegalovirus ; nonopportunistic disease , include limited following : progressive multifocal leukoencephalopathy , lymphoma , malignancy require systemic therapy Prior exposure ( &gt; 7 day ) tipranavir , saquinavir , ritonavir History clinically significant nervous system muscle disease , seizure disorder , psychiatric disorder might impair adherence protocol Taking know P450 3A enzymeinducing drug within 30 day study entry include follow : rifabutin , rifampin , carbamazepine , dexamethasone , phenobarbital , phenytoin , sulfadimidine , sulfinpyrazone , troleandomycin Hypersensitivity tipranavir , saquinavir , ritonavir Use interferon , interleukin , HIV vaccine , active immunization within 30 day study entry Taking investigational medication exception adefovir dipivoxil ( Preveon™ ) within 30 day study entry Pregnancy lactation ( serum βhuman chorionic gonadotrophin test negative within 14 day study entry ) Evidence substance abuse , investigator 's opinion could affect adherence protocol In investigator 's judgment , inability comply protocol requirement reason specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>